| IPO Company Profile |
| SEC Filings | Peer IPO Companies |
| Sensus Drug Development Corporation |
| 98 San Jacinto Boulevard, Suite 430, Austin, TX 78701 * (512) 487-2000 |
| The company is an emerging pharmaceutical company that is developing drugs to treat endocrine and metabolic diseases and disorders. |
| Manager | Tier | Phone |
| Merrill Lynch & Co. | Lead Manager | (212) 449-4600 |
| BancAmerica Robertson Stephens | Co-manager | (415) 989-8500 |
| Nationsbanc Montgomery Securities, Inc. | Co-manager | (415) 627-2100 |
| NASNTL: | SENS | Manufacturing: | SIC 2834 | |
| Type of Shares: | Common Shares | Filing Date: | 7/28/98 | |
| U.S. Shares Filed: | 3,000,000 | Filing Range: | $13.00 - $15.00 | |
| Non-U.S. Shares Filed: | 0 | Offering Amount: | $42,000,000 | |
| Primary Shares: | 3,000,000 | Expenses: | - | |
| Secondary Shares: | 0 | Post-IPO Shares: | ||
| Employees: | 15 |
| Issuer's Law Firm: | Cooley Godward Castro Huddleson & Tatum |
| Bank's Law Firm: | Brown & Wood |
| Registrar/Transfer Agent: | American Securities Transfer and Trust |
| Auditor: | Ernst & Young |
Dollar amounts in U.S. millions except for per share data | |||||
| 6 Month Ending Financials | |||||
| Full Year Audited Income | Latest Unaudited Income | Prior Audited Income | Balance Sheet | ||
| 12/31/97 | 6/30/98 | 6/30/97 | 6/30/98 | ||
| Revenue: | $0.00 | $0.00 | $0.00 | Assets: | $6.05 |
| Net Income: | -$12.45 | -$8.87 | -$3.57 | Curr Assets: | $5.50 |
| EPS: | -$0.82 | -$0.39 | Liabilities: | $4.08 | |
| Prior EPS: | Curr Liab: | $4.08 | |||
| Cash Flow/Oper: | -$8.91 | -$27.50 | -$13.07 | Equity: | $1.97 |
| Cash Flow/Fin: | $4.17 | $33.51 | $1.44 | Cash: | $3.77 |
| Cash Flow/Inv: | $0.01 | -$2.24 | -$1.84 | Working Cap: | $1.42 |
| Use of Proceeds |
| The proceeds from the proposed offering will be used for clinical trials of Trovert, additional research and development activities, commercialization of Trovert, including the establishment of a direct sales force and contract manufacturing, and for working capital and general corporate purposes including repayment of debt. |